NIAID supports an array of adjuvant research, from basic studies on immune receptors to clinical testing of new adjuvanted vaccine candidates. NIAID-funded programs involving adjuvant research include the following:
Established in 2003, this program was renewed in 2009 and again in 2014 to continue support for the identification and optimization of promising adjuvants. NIAID-funded researchers are screening thousands of compounds for adjuvant activity and have identified several promising leads.
NIAID initiated this program in 2008 to advance novel vaccine adjuvants toward licensure for human use. The program, which was renewed in 2013, supports the optimization of adjuvant candidates, vaccine formulation studies, and preclinical adjuvant pharmacology, toxicity, and efficacy studies.
NIAID established the Human Immunology Project Consortium (HIPC) in 2010 to create a public resource that characterizes the diverse states of the human immune system. HIPC investigators use modern analytic tools to profile the immune system before and after infection, vaccination, or treatment with an adjuvant. The information gained from HIPC promises to improve understanding of the human immune system and its regulation. It also will help scientists evaluate the safety and effectiveness of different vaccine formulations and administration techniques.
The NIAID-sponsored Vaccine and Treatment Evaluation Units (VTEUs), first established in 1962, have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure. Researchers at the VTEUs, which are located at universities and health centers across the United States, test novel vaccines and vaccine delivery methods. This includes the evaluation and study of adjuvants.
Last Updated September 30, 2014
Last Reviewed May 13, 2014